|
MEF2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.08630000001031E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.73780000000723E-05 |
| Normal-vs-Stage2 |
9.444600E-03 |
| Normal-vs-Stage3 |
1.16630000002171E-06 |
| Normal-vs-Stage4 |
1.46889999996791E-06 |
| Stage1-vs-Stage2 |
6.120000E-01 |
| Stage1-vs-Stage3 |
3.305600E-02 |
| Stage1-vs-Stage4 |
5.210100E-02 |
| Stage2-vs-Stage3 |
7.461900E-02 |
| Stage2-vs-Stage4 |
5.935900E-02 |
| Stage3-vs-Stage4 |
8.170000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.04219999980715E-07 |
| Normal-vs-AfricanAmerican |
1.243950E-01 |
| Normal-vs-Asian |
1.396580E-03 |
| Caucasian-vs-AfricanAmerican |
1.077580E-01 |
| Caucasian-vs-Asian |
5.401800E-01 |
| AfricanAmerican-vs-Asian |
3.476800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.91800000000275E-05 |
| Normal-vs-Female |
1.56217999999209E-05 |
| Male-vs-Female |
8.927200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.819900E-04 |
| Normal-vs-Age(41-60Yrs) |
2.62730000000211E-06 |
| Normal-vs-Age(61-80Yrs) |
3.67879999996212E-06 |
| Normal-vs-Age(81-100Yrs) |
2.192500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.305700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.213770E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.824600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.654200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.907000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.966400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.801800E-02 |
| Classical-VS-Follicular |
5.928800E-01 |
| Classical-VS-Other |
3.349600E-01 |
| Classical-VS-Normal |
7.50400000000262E-05 |
| Tall-VS-Follicular |
4.559900E-02 |
| Tall-VS-Other |
9.512400E-01 |
| Tall-VS-Normal |
1.77402000000049E-05 |
| Follicular-VS-Other |
2.984200E-01 |
| Follicular-VS-Normal |
3.935100E-03 |
| Other-VS-Normal |
1.102430E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.93116999999132E-05 |
| Normal-vs-N1 |
1.78432999999867E-05 |
| N0-vs-N1 |
3.060200E-01 |
|
|
